RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered...
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ETBEDMINSTER, N.J., Jan. 23, 2023 (GLOBE...
– State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts – – Awarded $1.9 million of state and local...
Primary IND for solid tumor program, T-Plex, supports simultaneous use of multiple TCRs to create customized, multiplexed TCR-T cell therapies...
WARRINGTON, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”) today announced it has...
Disc will obtain exclusive rights to MWTX-003 and other novel anti-TMPRSS6 antibodies in the United States, Europe and other territories...
TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”) is...
NFL Biosciences: CESTO II trial progressing on schedule Nine clinical sites active: more than 72% of the clinical trial participants...
NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5%...
TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R),...
-Company to present 18-month data results from ongoing HOPE-2 open label extension trial of CAP-1002 in patients with Duchenne muscular...
Study demonstrates targeted delivery devices functioned as designed when administered with food, potentially enabling non-fasted administrationSAN DIEGO, Jan. 19, 2023...
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”...
-- First ‘living medicine’ to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital...
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with...
SAN FRANCISCO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated...
MINNEAPOLIS, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the...
The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel...
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology...